Chargement en cours...
A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
Most patients with non-small cell lung cancer with common epidermal growth factor receptor (EGFR) mutations respond dramatically to EGFR tyrosine kinase inhibitors (TKIs), but data are limited on the response of tumours with uncommon mutations. We present the case of a 68-year-old man with stage IV...
Enregistré dans:
| Publié dans: | BMJ Case Rep |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Case Reports
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5990104/ https://ncbi.nlm.nih.gov/pubmed/29866661 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-219770 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|